HRS-3095

Unknown / undisclosed

Phase 2Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage study registered, not yet recruiting

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Chronic Spontaneous Urticaria
NCT07613866 · Chengdu Suncadia Medicine Co., Ltd.
2026-07 – 2027-03 · Chronic Spontaneous Urticaria
What this study did
Phase 1 (2)
Chronic Spontaneous Urticaria
NCT07686484 · Atridia Pty Ltd.
2026-07-27 – 2026-10-30 · Chronic Spontaneous Urticaria
What this study did

Competitive landscape

This drug's own stage for Chronic Spontaneous Urticaria: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-3095: this drugPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
RemibrutinibApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
BarzolvolimabPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
BriquilimabPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS-3095 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Chronic Spontaneous UrticariaNot yet recruiting
Est. primary completion 2026-12 · NCT07613866 · CT.gov ↗
What to watch

See the full readout calendar ↗